Novel Index Predicts Survival After Chemo in Pancreatic Cancer

This article originally appeared here.
Share this content:
Novel Index Predicts Survival After Chemo in Pancreatic Cancer
Novel Index Predicts Survival After Chemo in Pancreatic Cancer

MONDAY, May 16, 2016 (HealthDay News) -- For patients with advanced pancreatic cancer receiving chemotherapy, the systemic inflammation response index (SIRI), based on peripheral neutrophil, monocyte, and lymphocyte counts, can predict survival, according to a study published online May 6 in Cancer.

Qi Qi, M.D., from the Fudan University Shanghai Cancer Center, and colleagues developed the SIRI in a training set of 177 patients with advanced pancreatic cancer who had received palliative chemotherapy. The predictive ability was validated in two independent cohorts with 397 patients.

The researchers found that in the training cohort, patients with a SIRI ≥1.8 had a shorter time to progression (TTP) than patients with a SIRI <1.8 (hazard ratio, 2.348; P = 0.003); they also had shorter overall survival (OS) (hazard ratio, 2.789; P < 0.001). The two independent validation cohorts had comparable TTP and OS findings. SIRI was confirmed as an independent prognostic factor for TTP and OS in multivariate analysis. An increase in SIRI at week eight, compared with no change, correlated with poor TTP and OS; in contrast, a decrease in SIRI correlated with improved outcomes.

"The SIRI can be used to predict the survival of patients with pancreatic adenocarcinomas who receive chemotherapy, potentially allowing clinicians to improve treatment outcomes by identifying candidates for aggressive therapy," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ground Beef Recalled After E. Coli Outbreak

Ground Beef Recalled After <i>E. Coli</i> Outbreak

Beef was produced and packaged at Cargill Meat Solutions in Fort Morgan, Colo.

Prevalence of Alzheimer's, Related Dementia Set to Double

Prevalence of Alzheimer's, Related Dementia Set to Double

Alzheimer's disease and related dementias burden is expected to increase to 3.3 percent in 2060

Long-Term Outcomes of Breast Implants Explored

Long-Term Outcomes of Breast Implants Explored

Higher rates of Sjogren syndrome, scleroderma, RA, stillbirth, melanoma for silicone implants

is free, fast, and customized just for you!




Already a member?

Sign In Now »